SESSION TITLE: Fellow Case Report Poster - Diffuse Lung Disease I
SESSION TYPE: Affiliate Case Report Poster
PRESENTED ON: Tuesday, October 25, 2016 at 01:30 PM - 02:30 PM
INTRODUCTION: Nivolumab is a monoclonal antibody to programmed cell death (PD-1) receptor approved for the treatment of patients with advanced Non Small Cell Lung Cancer (NSCLC) who experience progression of disease on or after standard chemotherapy. Pneumonitis is one of the side effect of Nivolumab.